GSK 2831781

Drug Profile

GSK 2831781

Alternative Names: GSK2831781; GSK‘781; ImmuTune-IMP731; IMP-731

Latest Information Update: 16 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immutep
  • Developer GlaxoSmithKline
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T lymphocyte inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Plaque psoriasis

Most Recent Events

  • 08 Aug 2018 Phase-II clinical trials in Ulcerative colitis (Parenteral)
  • 08 Aug 2018 Prima BioMed has patent protection for GSK 2831781 in Canada
  • 25 Jul 2018 Phase-I clinical trials in Ulcerative colitis (Parenteral) (GlaxoSmithKline R&D update presentation, July 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top